JPMorgan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $67 from $69 and keeps an Overweight rating on the shares. The company’s Q4 results were broadly in line with expectations, the analyst tells investors in a research note. JPMorgan says it looks forward to Crispr’s pipeline updates later this year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target raised to $80 from $77 at Citi
- CRISPR Therapeutics: Casgevy Outperformance and 2026 Pipeline Catalysts Drive Raised $80 Target and Buy, High Risk Rating
- Crispr Therapeutics price target raised to $76 from $74 at Chardan
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Crispr Therapeutics price target raised to $82 from $80 at Needham